Published in Expert Opin Investig Drugs on July 01, 2010
Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother (2013) 0.95
MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother (2012) 0.85
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol (2014) 0.81
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ (2004) 9.93
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 8.65
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis (2006) 7.64
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis (2001) 6.92
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med (2000) 6.24
The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta (1967) 6.07
Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ (2007) 5.99
Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis (2007) 4.61
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis (2005) 4.42
Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol (1995) 4.39
Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis (2003) 4.28
Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep (1995) 4.19
Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol (2003) 4.00
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA (1994) 3.66
Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect (2007) 3.27
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol (2002) 3.24
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis (2005) 3.14
Lactobacillus sepsis associated with probiotic therapy. Pediatrics (2005) 3.02
Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis (2005) 2.68
A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med (2005) 2.58
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother (2008) 2.47
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother (2007) 2.43
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther (2005) 2.36
Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis (2006) 2.35
In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother (1991) 2.23
In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother (2004) 2.17
Treatment of Clostridium difficile infection. Clin Infect Dis (2008) 2.13
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis (2000) 2.06
Measures to control and prevent Clostridium difficile infection. Clin Infect Dis (2008) 2.04
Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis (2006) 2.03
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother (2002) 2.00
Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis (2005) 1.93
The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect (1998) 1.88
In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother (2004) 1.85
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother (2004) 1.85
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis (2001) 1.81
Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother (1990) 1.79
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother (2008) 1.71
Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother (2007) 1.68
In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother (2000) 1.65
Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut (1986) 1.61
Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol (2010) 1.56
Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med (1989) 1.41
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis (2009) 1.41
Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol (2005) 1.41
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis (2009) 1.40
Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis (1999) 1.38
Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev (2008) 1.35
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother (2005) 1.34
Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res (1994) 1.34
Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis (2003) 1.34
Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg (1995) 1.32
In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother (2000) 1.30
Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother (2001) 1.27
Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther (2000) 1.25
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol (2004) 1.24
Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother (2006) 1.20
Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol (2003) 1.20
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother (2003) 1.18
Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology (1985) 1.18
Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis (1998) 1.16
In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.16
Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs (2006) 1.15
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis (2009) 1.15
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev (2007) 1.15
Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe (2009) 1.14
Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol (2007) 1.14
Clostridium difficile--beyond antibiotics. N Engl J Med (2010) 1.14
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother (2008) 1.14
Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother (2004) 1.13
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother (2008) 1.12
In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect (2009) 1.12
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis (2006) 1.09
Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Infect Dis (2008) 1.07
Probiotics for recurrent Clostridium difficile disease. J Med Microbiol (2005) 1.06
Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect (2009) 1.05
Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis (2001) 1.05
In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother (2005) 1.03
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
Determination of survival, identity and stress resistance of probiotic bifidobacteria in bio-yoghurts. Lett Appl Microbiol (2006) 1.00
In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol (2010) 0.98
Probiotics: "living drugs". Am J Health Syst Pharm (2001) 0.96
Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother (2003) 0.95
In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Anaerobe (2004) 0.93
New drugs for Clostridium difficile infection. Clin Infect Dis (2006) 0.91
Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS (2006) 0.90
Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents (2009) 0.89
Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther (2001) 0.88
Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother (2002) 0.87
Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci (2005) 0.83
Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis (2006) 0.81
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet (2008) 2.79
Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis (2006) 2.35
Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg (2008) 2.09
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer (2014) 1.98
Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther (2006) 1.84
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother (2010) 1.69
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.63
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother (2006) 1.62
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
Vitamin A supplementation has divergent effects on norovirus infections and clinical symptoms among Mexican children. J Infect Dis (2007) 1.50
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg (2006) 1.46
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol (2007) 1.41
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother (2012) 1.33
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother (2009) 1.20
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis (2008) 1.15
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis (2007) 1.14
Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy (2007) 1.14
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol (2010) 1.12
A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis (2010) 1.11
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother (2012) 1.06
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother (2012) 1.05
Involvement of immunization-certified pharmacists with immunization activities. Ann Pharmacother (2003) 1.05
Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis (2009) 0.99
Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol (2011) 0.98
Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents (2009) 0.97
Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol (2008) 0.97
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol (2002) 0.97
PCR-based assay using occult blood detection cards for detection of diarrheagenic Escherichia coli in specimens from U.S. travelers to Mexico with acute diarrhea. J Clin Microbiol (2008) 0.95
Enteroaggregative Escherichia coli (EAEC): a cause of acute and persistent diarrhea of worldwide importance. J Infect Dis (2010) 0.93
Vitamin A supplementation reduces the monocyte chemoattractant protein-1 intestinal immune response of Mexican children. J Nutr (2006) 0.92
Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis (2012) 0.91
A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. Am J Pharm Educ (2013) 0.90
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel Dis (2013) 0.90
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother (2012) 0.90
Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci (2003) 0.87
In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health (2011) 0.87
Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses (2011) 0.87
A nosocomial outbreak of norovirus infection masquerading as clostridium difficile infection. Clin Infect Dis (2009) 0.87
Enteroaggregative Escherichia coli: an emerging pathogen in children. Semin Pediatr Infect Dis (2004) 0.87
New Developments in Traveler's Diarrhea. Gastroenterol Hepatol (N Y) (2011) 0.86
Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai (2011) 0.86
Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother (2006) 0.85
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin (2007) 0.84
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother (2013) 0.82
Epidemiology of travelers' diarrhea in Thailand. J Travel Med (2009) 0.82
Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. J Clin Microbiol (2011) 0.82
Biochemical and genetic diversity of enterotoxigenic Escherichia coli associated with diarrhea in United States students in Cuernavaca and Guadalajara, Mexico, 2004-2007. J Infect Dis (2010) 0.82
A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. J Travel Med (2011) 0.82
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol (2014) 0.81
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther (2010) 0.81
Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother (2010) 0.80
Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol (2012) 0.79
Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV AIDS (Auckl) (2013) 0.79
Epidemiology of Clostridium difficile-associated diarrhea in a Peruvian tertiary care hospital. Am J Trop Med Hyg (2007) 0.79
Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm (2010) 0.79
Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol (2008) 0.79
Association of virulence factor-positive and -negative enteroaggregative Escherichia coli and occurrence of clinical illness in travelers from the United States to Mexico. Am J Trop Med Hyg (2003) 0.79
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag (2009) 0.79
Impact of a pharmacotherapy alerting system on medication errors. Am J Health Syst Pharm (2013) 0.78
Coliform contamination of vegetables obtained from popular restaurants in Guadalajara, Mexico, and Houston, Texas. Clin Infect Dis (2008) 0.78
Risk factors associated with diarrhea among international visitors to Cuzco, Peru. Am J Trop Med Hyg (2006) 0.78
Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother (2006) 0.78
Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol (2010) 0.78
Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm (2011) 0.77
Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.77
Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci (2012) 0.77
Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother (2010) 0.77
Advances in the treatment of travelers' diarrhea. Curr Gastroenterol Rep (2011) 0.77
Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis (2013) 0.77
Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm (2012) 0.77
Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. PLoS One (2013) 0.77
Clostridium difficile-related death rates in Texas 1999-2005. J Infect (2009) 0.77
Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci (2009) 0.77
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother (2014) 0.76
Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. Diagn Microbiol Infect Dis (2002) 0.76
A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy (2012) 0.76
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol (2017) 0.75
Flat-panel versus 64-channel computed tomography for in vivo quantitative characterization of aortic atherosclerotic plaques. Int J Cardiol (2010) 0.75
An expert panel report of a proposed scientific model demonstrating the effectiveness of antibacterial handwash products. Am J Infect Control (2012) 0.75
Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm (2008) 0.75
Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. Curr Infect Dis Rep (2008) 0.75
Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia (2014) 0.75
Pilot of a patient-centered pharmacy practice model. Am J Health Syst Pharm (2012) 0.75
An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm (2006) 0.75
Pharmacists' perceptions of the effectiveness of antimicrobial control programs. Am J Health Syst Pharm (2006) 0.75
Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci (2005) 0.75
Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm (2010) 0.75